Ritlecitinib tosylate capsules | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
- Company
- Pfizer Inc.
- Medicine type
- Chemical medicine
- Therapeutic area
- Dermatology
- Indications recorded in the public source
- Treatment of severe alopecia areata in adults and adolescents aged 12 years or older. The prescribing information does not recommend use with other JAK inhibitors, biologic immunomodulators, ciclosporin, or other potent immunosuppressants.
- Indication source and scope
- 2025-07-01
- Prescribing-information limitations
- Complete official prescribing information obtained. Mainland China label.
- China availability status
- Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- Overseas status
- Japan, United Kingdom: local approval / launch announcements and official price sources obtained. Indications and dates are specified in each price record; other markets not exhaustively reviewed.
- Insurance classification
- Not matched in the 2025 national list; manual review pending
- Insurance edition
- 2025 edition; effective 1 January 2026
- Insurance verification notes
- No match in the extracted directory is not proof of exclusion. Compound formulations still require manual review.
Sources
- https://www.nmpa.gov.cn/directory/web/nmpa/images/1707039824076019627.pdf
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
- https://labeling.pfizer.com/ShowLabeling.aspx?id=19996
Open the interactive record, public price references and discussions